https://twitter.com/GlomCon/status/1727822600351703381#KidneyWk pearls continues: Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Focal Segmental Glomerulosclerosis (FSGS): Results from the Phase 3 DUPLEX Trial Presented by no one less than @rheault_m Watch here https://bit.ly/49T8txh https://bit.ly/49JGEHD https://bit.ly/49MMgAT
— GlomCon (@GlomCon) Nov 23, 2023
Thursday, November 23, 2023
@GlomCon
http://twitter.com/GlomCon
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment